Flecainidi acetas - etsinnän tulokset

Yhdysvallat - englanti - NLM (National Library of Medicine)

flecainide acetate tablet

bryant ranch prepack - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets, usp are indicated for the prevention of — paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms — paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets, usp are also indicated for the prevention of — documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets, usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets, usp are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarr

Yhdysvallat - englanti - NLM (National Library of Medicine)

flecainide acetate tablet

epic pharma, llc - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets, usp are indicated for the prevention of: - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets, usp are also indicated for the prevention of: - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets, usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets, usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets, usp should not be used in patients with recent myocardial infarction. (see boxed warnings.) use of flecainide acetate tablets, usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings.) as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, usp favorably affects survival or the incidence of sudden death. flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree av block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug.

Yhdysvallat - englanti - NLM (National Library of Medicine)

flecainide acetate tablet

chartwell rx, llc - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate is indicated for the prevention of — paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms — paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate is also indicated for the prevention of — documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate, its use should be reserved for patients in

Australia - englanti - Department of Health (Therapeutic Goods Administration)

flecainide bnm flecainide acetate 50 mg tablet blister pack

boucher & muir pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; maize starch; magnesium stearate - 1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes. b) due to dual av nodal pathways in patients with debilitating symptoms. c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms.,although flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide bnm tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

flecainide bnm flecainide acetate 100 mg tablet blister pack

boucher & muir pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; croscarmellose sodium; maize starch - 1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes. b) due to dual av nodal pathways in patients with debilitating symptoms. c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms.,although flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide bnm tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.